TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19571077
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine infusion and Placebo
Study: 16624769
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 mixed solution inhalation
Study: 16624769
Drug: Gentamycin sulfate
Normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN SULFATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin sulfate mixed solution inhalation
Study: 8277057
Drug: Luting agents
Normalized name: Solvents and diluting agents, incl. irrigating solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luting agents with resin restorative systems
Study: 8277057
Drug: Luting agents
Normalized name: Solvents and diluting agents, incl. irrigating solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luting agents with ceramic restorative systems
Study: 20572863
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in knowledge and attitudes related to oral health
Study: 10326791
Drug: fenretinide (4‐HPR)
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenretinide (4‐HPR) administered for a mean of 40 months
Study: 26337944
Drug: High-dose ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ranibizumab (1.0/0.1 ml or 2.0 mg/0.05 ml; n=15)
Study: 26337944
Drug: Standard-dose ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose ranibizumab (0.5 mg/0.05 ml; n=5)
Study: 11165993
Drug: Misoprostol in
Normalized name: Product containing misoprostol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol in combination with NSAID
Study: 9432097
Drug: Terbutaline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (3 mg from MDI)
Study: 3690029
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate therapy
Study: 23795326
Drug: Preoperative patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative patient education (oral and written)
Study: 2678885
Drug: Savlon as
Normalized name: Savlon Dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savlon as a cleansing agent before ocular surgery
Study: 4855182
Drug: Treatment prognosis
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment prognosis ratings by therapists
Study: 25858909
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 µg twice daily
Study: 25858909
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 µg twice daily (excluding patients who changed prednisolone dose)
Study: 11211366
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - doses: placebo, low, middle, high
Study: 11211366
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - total daily dose limit of 35 mg for children weighing less than 25 kg
Study: 9644316
Drug: Weekly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly chemotherapy (Arm B): CDDP (40 mg/m2), VDS (3 mg/m2), MMC (4 mg/m2) on day 1, followed by CDDP (20 mg/m2), VDS (1.5 mg/m2), MMC (2 mg/m2) weekly.
Study: 9644316
Drug: Monthly chemotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly chemotherapy (Arm A): CDDP (80 mg/m2) monthly on day 1, VDS (3 mg/m2) on days 1 and 8, MMC (8 mg/m2) on day 1.
Study: 31564829
Drug: New generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generic formulation of S-1
Study: 31564829
Drug: Branded reference
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded reference formulation of S-1
Study: 22925226
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at a maximum dose of 3000 mg
Study: 16945231
Drug: Diazepam administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam administered
Study: 16945231
Drug: Midazolam administered
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered
Study: 16945231
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with saline administration
Study: 10356916
Drug: Metabolic complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolic complex of amino acids (100 mg 3 times a day for 20 days)
Study: 8568118
Drug: Acetate alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate alone (56.25 mmol/L)
Study: 8568118
Drug: Acetate plus
Normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate plus propionate (56.25 mmol/L + 18.75 mmol/L)
Study: 8568118
Drug: Acetate plus
Normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate plus calcium (56.25 mmol/L + 50 mmol/L)
Study: 8568118
Drug: Acetate, propionate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate, propionate, and calcium together (56.25 mmol/L + 18.75 mmol/L + 50 mmol/L)
Study: 8568118
Drug: Propionate alone
Normalized name: propionate
DrugBank: Propionate ion (DB19384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionate alone (18.75 mmol/L)
Study: 1836088
Drug: lynestrenol 5-10
Normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lynestrenol 5-10 mg
Study: 1836088
Drug: DMPA (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA (intramuscular administration)
Study: 7058319
Drug: bezafibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (3 X 200 mg daily)
Study: 7058319
Drug: colestipol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: colestipol (2 X 10 g per day)
Study: 7058319
Drug: probucol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: probucol (2 X 500 mg daily)
Study: 7058319
Drug: dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dietary treatment alone
Study: 27276431
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 25 mg ARA/100 kcal
Study: 27276431
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 34 mg ARA/100 kcal
Study: 27276431
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 0 mg ARA/100 kcal
Study: 21517195
Drug: Interaction between
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interaction between DD and treatment condition
Study: 16867025
Drug: Zolpidem modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem modified-release (MR) 12.5 mg
Study: 16867025
Drug: Zolpidem immediate-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem immediate-release (IR) 10 mg
Study: 16867025
Drug: Zolpidem intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem intravenous (i.v.) infusion 8 mg
Study: 1354275
Drug: Fluorouracil (1
Normalized name: Fluorouracil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (1 g per day) plus heparin (10,000 U per day) during and after surgery for 7 days
Study: 6352304
Drug: Inhaled beta-2-agonists
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta-2-agonists (2.5 mg terbutaline)
Study: 6352304
Drug: Intramuscular dosed
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular dosed beta-2-agonists (1/4 mg terbutaline)
Study: 30650256
Drug: Topical GSK1940029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GSK1940029 (0.3% and 1%, occluded application)
Study: 30650256
Drug: Topical GSK1940029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GSK1940029 (0.1% to 1%, single and repeat doses, occluded and nonoccluded applications)
Study: 30650256
Drug: Topical GSK1940029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GSK1940029 (0.1% to 1%, occluded application)
Study: 8829954
Drug: Lipid-lowering drugs
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drugs and diet (2 to 3 years)
Study: 346140
Drug: Bulk forming
Normalized name: Bulk forming laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk forming agent (ispaghula husk)
Study: 31345179
Drug: APAD intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: APAD intervention (thrice-weekly moderate-intensity mixed aerobic and resistance exercise sessions and 9 dietetic consultations)
Study: 29059644
Drug: Resveratrol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol at a dose of 100 mg per os daily added to standard therapy
Study: 29059644
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Β‐blockers, statins, aspirin)
Study: 15513305
Drug: Amlodipine-based antihypertensive
Normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine-based antihypertensive therapy
Study: 11757505
Drug: Folate treatment
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate treatment (1 mg folic acid, 400 microg vitamin B12, 10 mg pyridoxine)
Study: 11757505
Drug: Folate treatment
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate treatment
Study: 3003206
Drug: Acyclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (10 mg/kg) administered intravenously at 8-hr intervals for seven days
Study: 3003206
Drug: Acyclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (10 mg/kg)
Study: 31330457
Drug: Multiple-injection paravertebral
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-injection paravertebral block (PVB)
Study: 31330457
Drug: Single-injection erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection erector spinae plane block (ESPB)
Study: 10073741
Drug: xamoterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol (2 x 200 mg day(‐1) p.o.)
Study: 10073741
Drug: xamoterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol (2 x 200 mg day(‐1) p.o.) after 2 weeks
Study: 10073741
Drug: ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketotifen (2 x 1 mg day(‐1) p.o.)
Study: 7030976
Drug: Proxyphylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxyphylline (500 mg orally three times daily) + Salbutamol (3 mg p.o.)
Study: 7030976
Drug: Proxyphylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxyphylline (500 mg orally three times daily) + Placebo
Study: 31994510
Drug: Migrepam (zolmitriptan)
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Migrepam (zolmitriptan) 2.5 mg
Study: 26785820
Drug: Quercetin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (500 mg daily for 4 weeks)
Study: 19029269
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel (APG)
Study: 20605484
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard surgical treatment without APG)
Study: 15957842
Drug: Jinye Baidu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 30 mg daily
Study: 15957842
Drug: Jinye Baidu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 20 mg daily
Study: 15957842
Drug: Jinye Baidu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinye Baidu granule (JBG) combined with zinc gluconate tablet at a dose of 10 mg daily
Study: 10091737
Drug: Adjuvant CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CMF chemotherapy (6 courses)
Study: 10091737
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no systemic adjuvant treatment)
Study: 7751496
Drug: Relaxation-biofeedback training
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Relaxation-biofeedback training with propranolol (60, 120, or 180 mg/day)
Study: 31648072
Drug: Cookstove treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cookstove treatments
Study: 30057406
Drug: Trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.3 mg/m2
Study: 30057406
Drug: Gemcitabine 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 900 mg/m2 and docetaxel 75 mg/m2
Study: 27502725
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus second-line chemotherapy
Study: 18063879
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 6 mg/m2 and standard-dose cytarabine 100 mg/m2
Study: 18063879
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 with standard- and high-dose cytarabine and anthracyclines
Study: 18063879
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) 3 mg/m2 and high-dose cytarabine 3 g/m2
Study: 30361792
Drug: Ultramicronized palmitoylethanolamide
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultramicronized palmitoylethanolamide 600 mg twice daily for 60 days
Study: 18765504
Drug: Warfarin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin exposure (1-month time window)
Study: 18765504
Drug: Warfarin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin exposure (1 to 3 prescriptions in the previous year)
Study: 18765504
Drug: Warfarin exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin exposure (1-year time window using case-time-control approach)
Study: 11391748
Drug: Intravenous amantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amantadine (200 mg)
Study: 8607888
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral pamidronate/day
Study: 1393807
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection (group 1)
Study: 1393807
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection (group 2)
Study: 2856908
Drug: Cimetidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.0 mg/kg X h)
Study: 2856908
Drug: Ranitidine (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.16 mg/kg X h)
Study: 30782696
Drug: Continuous high-flow
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-flow nasal oxygen therapy (usual care)
Study: 11961629
Drug: Local wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound infiltration with 10 ml of 0.5% bupivacaine (group I, n = 50)
Study: 11961629
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of the extraperitoneal space with 40 ml of 0.25% bupivacaine (group II, n = 50)
Study: 16988209
Drug: Lansoprazole (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (60 mg)
Study: 10510158
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg)
Study: 7493428
Drug: Water restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water restriction (200 ml/day) during low-sodium diet
Study: 7493428
Drug: Hydrated group
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrated group (1800 ml/day water intake) during low-sodium diet
Study: 1372508
Drug: Penicillin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (5 mu twice, 6 hours apart)
Study: 1372508
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (without penicillin or placebo)
Study: 3876579
Drug: Analgesic electrical
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic electrical stimulation (AES)
Study: 15480323
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 1 year
Study: 9059210
Drug: Continuous brachial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous brachial plexus infusion of butorphanol 6 mg with 0.5% mepivacaine
Study: 9059210
Drug: Bolus of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of butorphanol 1 mg with 1.5% mepivacaine and continuous brachial plexus infusion of 0.5% mepivacaine with butorphanol 6 mg
Study: 3512124
Drug: Moricizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (10 mg/kg/day)
Study: 18775020
Drug: AZD7371 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7371 20 mg
Study: 18775020
Drug: AZD7371 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7371 5 mg
Study: 16214830
Drug: ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg bid
Study: 16214830
Drug: ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 10 mg bid
Study: 16214830
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg bid
Study: 16214830
Drug: atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50 mg od
Study: 10503809
Drug: Aminoguanidine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoguanidine (two dose levels)
Study: 1777372
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 or 50 mg twice daily)
Study: 6118768
Drug: normal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal treatment (control)
Study: 31544381
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with comprehensive rehabilitation therapy
Study: 31544381
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation therapy alone (Control group)
Study: 27996217
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (ET) program, 12-week, twice a week, 60-minute sessions
Study: 25367691
Drug: R. emodi
Approvals — FDA: no, EMA: no, PMDA: no
Description: R. emodi capsules (two times a day, two days before menstruation and continued for the first three days of menstruation)
Study: 25367691
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid capsules (three times a day on the same protocol)
Study: 19299239
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/day orally)
Study: 19299239
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg/day orally)
Study: 17534819
Drug: Topical levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical levofloxacin (three times on the day before surgery and seven times on the day of surgery)
Study: 17534819
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (200 mg twice on the day before surgery and 200 mg at 3 hours before surgery)
Study: 17534819
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical and oral levofloxacin (according to the above schedules)
Study: 15486815
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acarbose three times a day for eight weeks
Study: 7863754
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who did not attend treatment regularly (36 patients)
Study: 7863754
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who attended treatment regularly but had missed at least one treatment (50 patients)
Study: 30644326
Drug: Ropinirole (agonist)
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole (agonist)
Study: 22981241
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 10 mg for 60 days
Study: 20212518
Drug: Nortriptyline (tricyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (tricyclic antidepressant)
Study: 16414143
Drug: Amlodipine and
Normalized name: amlodipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine and ramipril added to previous antihypertensive treatment for 12 weeks
Study: 1740491
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (1 mg/day, orally) for 5 or 15 days
Study: 1740491
Drug: Progesterone (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (5-10 mg/day, im, for 2 days) added after RU 486
Study: 10268816
Drug: Modeling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modeling plus rehearsal (treatment group)